Evaluating the enantioselective degradation and novel metabolites following a single oral dose of metalaxyl in mice

• The distribution, degradation and excretion of metalaxyl in male mice were enantioselective.
• R-metalaxyl was much higher than S-metalaxyl in plasma, liver, heart, lung, urine and feces.
• Biotransformation reactions in mice were hydroxylation, demethylation and didemethylation.
• Hydroxymetalaxyl metabolites were the main metabolites in mice after oral administration.

Metalaxyl [N-(2,6-dimethylphenyl)-N-(methoxyacetyl)-D,L-alaninemethylester] is a systemic fungicide widely used in agriculture. In this study, the enantioselective distribution, degradation and excretion of metalaxyl were investigated after oral gavage administration of rac-metalaxyl to mice. Concentration of metalaxyl and its enantiomers was determined by HPLC–MS/MS. The results showed that R-metalaxyl was much higher than S-metalaxyl in heart, liver, lung, urine and feces. As for the strong first pass effect, concentrations of metalaxyl in liver were much higher than those in other tissues. The total body clearance (CL) of metalaxyl in mice was 1.77 L h−1 kg−1 and degradation half-lives of (t1/2) of S-metalaxyl and R-metalaxyl in liver were 2.2 h and 3.0 h, respectively. Such results indicated the enantioselectivity of metalaxyl lies in distribution, degradation and excretion processes in mice. Main metabolites were also determined and biotransformation reactions were hydroxylation, demethylation and didemethylation. Furthermore, metabolite concentrations in urine and feces were much higher than those in tissues. These results may have potential implications to predict toxicity and provide additional information associated with adverse health effects for risk assessment of metalaxyl.

Graphical AbstractFigure optionsDownload as PowerPoint slide